Cipla Current Share Price | Cipla Stock Screener
CIPLA
Pharmaceuticals
Cipla Current Stock Price Today
Live Share Price NSE
₹1394.50
▲
18.20 (1.32%)
Live Share Price BSE
₹1371.45
▼
-0.80 (-0.06%)
As of September 18, 2026, the live Cipla share price (NSE: CIPLA) is ₹1,394.50 on NSE and ₹1,371.45 on BSE, up 1.32% from the previous close, with shares trading between ₹1,371.70 and ₹1,394.50 in today's trading session, and a 52-week range of ₹1,192.40–₹1,645.10.
Browse CIPLA complete financial statements to support your investment research.
Use the Cipla stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Cipla Market Cap
₹109,705.39 Cr.
CIPLA P/E Ratio (TTM)
32.76
Cipla P/B Ratio
3.19
EPS (TTM)
₹48.03
Dividend Yield
0.96%
Debt to Equity
0.02
CIPLA 52 Week High
₹1645.10
Cipla 52 Week Low
₹1192.40
Operating Margin
16.00%
Profit Margin
10.78%
CIPLA Revenue (TTM)
₹7,288.00
EBITDA
₹1,361.00
Net Income
₹786.00
Total Assets
₹42,496.00
Total Equity
₹34,520.00
Cipla Current Share Price Chart
Track the current Cipla share price and stock price with an interactive chart. Analyse CIPLA price trends, trading volume, historical performance, and volatility across different timeframes — the complete Cipla stock quote in one place.
Cipla Company Profile - Fundamental Screener
Screen Cipla company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CIPLA shares.
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Y K Hamied
ISIN
INE059A01026
Website
https://www.cipla.com
Cipla Balance Sheet Screener
Screen CIPLA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 42,496 | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 |
| Current Assets | 24,146 | 23,249 | 19,392 | 16,805 | 14,711 | 13,210 | 11,706 | 12,427 | 10,814 | 8,736 |
| Fixed Assets | 12,434 | 10,006 | 9,607 | 9,161 | 9,683 | 9,516 | 9,683 | 9,608 | 9,950 | 9,492 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 962 | 614 | 670 | 640 | 1,071 | 1,975 | 3,212 | 4,848 | 4,447 | 4,682 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 34,520 | 31,289 | 26,802 | 23,714 | 21,117 | 18,586 | 16,057 | 15,344 | 14,582 | 12,982 |
| Share Capital | 162 | 162 | 162 | 161 | 161 | 161 | 161 | 161 | 161 | 161 |
| Reserves & Surplus | 34,270 | 31,032 | 26,545 | 23,246 | 20,680 | 18,165 | 15,602 | 14,851 | 14,068 | 12,383 |
Cipla Income Statement Screener - Profit & Revenue Analysis
Screen Cipla income statement and profit fundamentals.
Analyze CIPLA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Cipla share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,288 | 6,612 | 7,169 | 7,716 | 7,096 | 6,887 | 7,183 | 7,152 | 6,785 | 6,332 | 6,690 | 6,766 | 6,406 | 5,801 | 5,845 |
| Expenses | 5,927 | 5,586 | 6,095 | 5,695 | 5,179 | 5,192 | 5,084 | 5,165 | 4,978 | 4,847 | 5,051 | 4,944 | 4,835 | 4,748 | 4,403 |
| EBITDA | 1,361 | 1,026 | 1,074 | 2,022 | 1,916 | 1,695 | 2,099 | 1,986 | 1,807 | 1,484 | 1,639 | 1,821 | 1,571 | 1,053 | 1,442 |
| Operating Profit % | 16.00% | 14.00% | 12.00% | 24.00% | 24.00% | 21.00% | 27.00% | 26.00% | 25.00% | 20.00% | 22.00% | 25.00% | 23.00% | 16.00% | 23.00% |
| Depreciation | 304 | 383 | 278 | 297 | 253 | 309 | 280 | 272 | 247 | 288 | 233 | 290 | 239 | 346 | 272 |
| Interest | 17 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 18 | 18 | 30 | 26 | 16 | 34 | 32 |
| Profit Before Tax | 1,082 | 707 | 893 | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 | 1,611 | 1,259 | 1,474 | 1,594 | 1,375 | 745 | 1,218 |
| Tax | 296 | 165 | 219 | 500 | 478 | 290 | 342 | 484 | 436 | 327 | 405 | 439 | 377 | 224 | 410 |
| Net Profit | 786 | 543 | 674 | 1,353 | 1,292 | 1,214 | 1,575 | 1,305 | 1,176 | 932 | 1,068 | 1,155 | 998 | 522 | 808 |
| EPS | 9.77 | 6.87 | 8.37 | 16.73 | 16.07 | 15.13 | 19.45 | 16.13 | 14.58 | 11.63 | 13.08 | 14.01 | 12.34 | 6.51 | 9.92 |
Cipla Cash Flow Screener - Liquidity Fundamentals
Screen CIPLA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,940 | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 | 1,691 | 1,463 | 2,382 |
| Investing Activities | -2,234 | -3,682 | -2,983 | -2,376 | -1,858 | -2,374 | 114 | -1,688 | -834 | -1,304 |
| Financing Activities | -1,234 | -1,293 | -1,200 | -958 | -1,600 | -1,240 | -2,949 | -349 | -386 | -1,326 |
| Net Cash Flow | 473 | 30 | -49 | -97 | -132 | 141 | 234 | -345 | 243 | -248 |
Cipla Shareholding Pattern Screener
See Cipla shareholding pattern with promoter, FII, and DII holdings.
Check Cipla promoter holding and ownership changes for CIPLA on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 29.21% | 29.21% | 29.20% | 29.19% | 29.21% | 29.21% | 33.47% | 30.91% |
| FII Holding | 22.56% | 20.21% | 26.28% | 25.25% | 24.55% | 23.93% | 25.83% | 27.81% |
| DII Holding | 31.97% | 34.63% | 28.15% | 29.26% | 30.25% | 30.72% | 24.42% | 24.95% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.98% | 13.74% | 14.13% | 14.10% | 13.82% | 13.84% | 14.20% | 14.24% |
| Other Holding | 2.28% | 2.20% | 2.23% | 2.20% | 2.16% | 2.29% | 2.08% | 2.09% |
| Shareholder Count | 584,217 | 578,679 | 543,420 | 549,655 | 534,587 | 540,521 | 436,154 | 463,569 |
Cipla Share Dividend Screener - Share Yield Analysis
Check Cipla dividend history with payout and yield data.
View Cipla dividend details including ex-dates and amounts for CIPLA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹13.00 | 0.96% |
| 2025-March | ₹16.00 | 1.31% |
| 2024-March | ₹13.00 | 0.90% |
| 2023-March | ₹8.50 | 0.57% |
| 2022-March | ₹5.00 | 0.56% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹4.00 | 0.49% |
| 2019-March | ₹3.00 | 0.71% |
| 2018-March | ₹3.00 | 0.57% |
| 2017-March | ₹2.00 | 0.37% |
Cipla Stock Index Membership
See which indices include Cipla stock.
Check CIPLA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX DOL100
BSE INDEX ESG100
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MFG
BSE INDEX SNSX50
BSE SENSEX SIXTY
BSE SENSEX SIXTY 65:35
GIFT NIFTY
INDIA VIX
NIFTY 100
NIFTY 200
NIFTY 50
NIFTY 500
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY GROWSECT 15
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY QUALITY LOW VOLATILITY 30
NIFTY SHARIAH 25
NIFTY TOTAL MKT
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 LOWVOL30
NIFTY50 EQL WGT
NIFTY50 SHARIAH
NIFTY50 VALUE 20
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
SENSEX NEXT 30
Cipla Market Events Screener - Corporate Actions
Get Cipla corporate actions including splits, bonuses, and buybacks.
Check Cipla stock events that may affect CIPLA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | -1.26% |
| 2026-06-25 | 2026-06-25 | Annual General Meeting | NA | 11.27% |
| 2026-06-05 | 2026-06-05 | Dividend | ₹ 13.00 /share | 8.23% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 5.66% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -9.40% |
| 2025-10-30 | 2025-10-30 | Quarterly Result Announcement | NA | 3.54% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -1.20% |
| 2025-07-16 | 2025-07-16 | Annual General Meeting | NA | -1.37% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 13.00 /share | 0.08% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 3.00 /share | 0.08% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 6.81% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -7.57% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -9.10% |
| 2024-08-20 | 2024-08-20 | Annual General Meeting | NA | 15.95% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 13.00 /share | 13.79% |
Cipla Competitors Screener - Peer Comparison
Screen CIPLA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 444,717 | 36.34 | 61,674 | 12.69% | 11,565 | 38.94 |
| Divis Laboratories | 243,116 | 83.41 | 11,067 | 13.95% | 2,568 | 57.81 |
| Torrent Pharmaceuticals | 183,052 | 85.57 | 13,886 | 20.34% | 2,138 | 42.03 |
| Zydus Life Science | 111,440 | 23.87 | 27,658 | 17.64% | 5,026 | 43.86 |
| Cipla | 109,705 | 32.76 | 29,045 | 2.24% | 3,870 | 35.04 |
| Laurus Labs | 102,870 | 95.29 | 6,868 | 22.01% | 890 | 56.63 |
| Dr Reddys Laboratories | 95,152 | 30.15 | 35,059 | 3.90% | 4,158 | 39.81 |
| Aurobindo Pharma | 94,535 | 25.82 | 34,145 | 5.56% | 3,503 | 49.75 |
| Lupin | 93,504 | 16.93 | 29,039 | 26.75% | 5,356 | 22.87 |
| Mankind Pharma | 92,759 | 45.72 | 14,636 | 14.85% | 1,938 | 34.16 |
Cipla Company Announcements - News Screener
Screen CIPLA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-03 | Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-28 | Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip Long Island NY USA | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Restructuring | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-26 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-08-25 | USFDA Inspection At CompanyS Manufacturing Facility In Pithampur India | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2026-08-11 | Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-04 | Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-07-27 | Cipla Receives U.S. FDA Approval For Generic Advair Diskus® | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-23 | Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-23 | Grant Of Stock Option And Employee Stock Appreciation Rights | - |
| 2026-07-23 | Announcement under Regulation 30 (LODR)-Change in Management | - |